Price (from): €6,000 / day
• Steve Jolley is a subject matter expert in all areas of global safety compliance and signal detection and is a frequent speaker at leading industry events with FDA, EMA, and MHRA on the topics of auditing and signaling
• Steve has 30 years’ experience in drug safety & pharmacovigilance and has worked with over 200 clients worldwide. He holds degrees in mathematics and computer science from Cambridge University, England.
• He is an Adjunct Professor at Rutgers University and teaches part of their Master's degree in Drug Safety and Pharmacovigilance.
• Steve has conducted over 200 audits for pharmaceutical companies in the US, EU, India, and Japan in order to prepare for both FDA and EU pharmacovigilance inspections.
• Steve was elected chairperson of the DIA Clinical Safety and Pharmacovigilance steering committee for North America. He is a member of DIA’s training faculty and instructs as part of DIA’s Clinical Safety and Pharmacovigilance Certificate Program.
About the training
This training course is designed to give pharmaceutical and biologic companies operating in the US an introduction to the fundamentals of product safety and regulatory compliance. It will also give you a jump-start on how to prevent common problems that are found during regulatory inspections for drug safety and pharmacovigilance. It will include examples based on the top ten findings by FDA pharmacovigilance inspectors. You will be able to use this information straight away to make the changes you need to address these common failings and avoid the findings.
You can be sure regulatory authorities will inspect your drug safety operations - and there is no excuse for poor preparation.
This training course is designed to give pharmaceutical firms operating in the US practical information, best practices and insight to help ensure compliance with the most recent drug safety and pharmacovigilance regulations.
An understanding of FDA regulatory requirements for drug safety; Knowledge of how to collect, assess, report and analyze adverse events to meet FDA requirements
Overview of the US regulatory framework
The top ten findings from FDA pharmacovigilance inspections; The objectives and components of a pharmacovigilance audit
Practical steps to help you begin and implement your audit; Examples of what NOT to do
Whether you're planning an internal audit of your processes, anticipating an audit from a business partner, or preparing for your FDA inspection, this course will give both old hands and new staff the insights needed to be ready for regulatory scrutiny of
More trainings of the trainerImpact of the European Pharmacovigilance Legislation on International Companies Introduction to Drug Safety – US and EU Requirements Signal Detection Training Course